NSF names three new I-Corps Hubs expanding the National Innovation Network across the U.S.

NSF I-Corps Hubs now include colleges and universities across the country

The U.S. National Science Foundation today announced the addition of three new NSF Innovation Corps (NSF I-Corps™) Hubs that will scale the NSF-led National Innovation Network (NIN), accelerating the translation of discoveries into new solutions that benefit society and the economy. Each NSF I-Corps Hub may receive up to $3 million per year for five years and comprises a regional alliance of at least eight universities. Combined with the existing 10 NSF I-Corps Hubs, these 13 NSF I-Corps Hubs presently span 48 states. See the interactive NSF I-Corps Hubs map.


NSF I-Corps Hubs provide experiential entrepreneurial training to researchers across all fields of science and engineering. I-Corps Hubs form the operational backbone of the NIN, a network of universities, NSF-funded researchers, established entrepreneurs, local and regional entrepreneurial communities and other federal agencies, that collectively help researchers learn to investigate the commercial potential of fundamental discoveries in science and engineering. The NSF I-Corps Hubs work collaboratively to build and sustain an innovation ecosystem that engages all Americans throughout the U.S.


“The goal of the I-Corps program is to deploy experiential education to help researchers reduce the time necessary to translate promising ideas from laboratory benches to widespread implementation that in turn impacts economic growth regionally and nationally,” said Erwin Gianchandani, NSF assistant director for Technology, Innovation and Partnerships. “Each regional NSF I-Corps Hub provides training essential in entrepreneurship and customer discovery, leading to new products, startups and jobs. In effect, we are investing in the next generation of entrepreneurs for our nation.”


Established in 2011, the NSF I-Corps program is designed to nurture the commercialization of deep technologies, which grow from discoveries in fundamental and use-inspired science and engineering. Since its inception, over 3,600 NSF I-Corps teams have participated in the I-Corps program. The strategic goals of the NSF I-Corps Hubs are technology translation, entrepreneurial training and workforce development, economic impact and collaboration and inclusion.


Listed below are the new NSF I-Corps Hubs and partner institutions:



NSF I-Corps Hub: Northwest region – NSF 2430389
 University of California, Berkeley - Lead
Oregon State University
University of Alaska Fairbanks 
University of California, Davis
University of California, Irvine
University of California, San Francisco
University of California, Santa Cruz
University of Washington


NSF I-Corps Hub: Southeast region – NSF 2430380 
 Georgia Tech - Lead
Clemson University
Morehouse College
The University of Alabama
University of Central Florida
University of Florida
University of Miami
University of South Florida


NSF I-Corps Hub: New England region – NSF 2430342 
 Massachusetts Institute of Technology - Lead
Brown University
Harvard University
Northeastern University
Tufts University
University of Maine
University of Massachusetts Amherst 
University of New Hampshire

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS